中文
EN
About us
Company Introduction
Corporate History
Business Introduction
Corporate Governance
Company Culture
Corporate Honors
R&D and Innovation
R&D System and Platforms
Innovation Strategy
Innovation Pipeline
Achievements
Products
Drug Products
Next-gen Therapies
APIs
Boranes
Services
CDMO
Project Collaboration
In-/Out-Licensing
Joint Venture
Sustainable
EHS
Energy
Quality
Supplier
News Center
2026
2025
2024
2023
2022
2021
Join Us
Talent Philosophy
Talent Development
Salary and Benefits
Campus Recruiting
Social Recruitment
Contact Us
Online Message
Blog Center
In 2026
In 2025
In 2024
In 2023
In 2022
In 2021
In 2020
In 2019
In 2018
In 2017
In 2016
Viwit Pharmaceuticals to Showcase at DCAT Week 2026, Invites Global Partners to New York
Dr. Keene Wei, President of Viwit, Invited to Speak at the 2026 In Vivo Cell Therapy Innovation Summit
Innovation Drives Development, Focus Makes a "Little Giant": Viwit Recognized as a National Specialized, Refined, Distinctive, and Innovative "Little Giant" Enterprise in the Seventh Batch!
Viwit Pharmaceuticals Co., Ltd. Embarks on a New Journey: Fully Focused on Innovation, Driving the Future with Insight and Science
Viwit Pharmaceuticals Granted "Radiation Safety License": A Dual Milestone in Compliance and Innovation
Advancing into a New Chapter: Viwit Pharma Officially Launches Frontier Exploration in Targeted Gene and Cell Therapies
Viwit Pharmaceuticals' Bimatoprost Eye Drops Receive Official Approval by China NMPA
Recently, Viwit Pharmaceuticals received the "Drug registration certificate" issued by China National Medical Products Administration (NMPA) for Bimatoprost Eye Drops. The approval number is H20244103. This signifies that the product has received official approval for the Chinese market and has successfully passed the generic drug consistency evaluation, thereby becoming the second domestic generic drug of its kind.
09
/
07
Viwit Pharmaceuticals' Gadoterate Meglumine Injection Receives Official Approval by China NMPA
Viwit Pharmaceuticals proudly announces the receipt of the "Drug Supplementary Application Approval Notice" from the National Medical Products Administration (NMPA) for their Gadoterate Meglumine Injection. This approval includes the following strengths: 10 mL containing 3.769 g, 15 mL containing 5.654 g, and 20 mL containing 7.538 g. The corresponding approval numbers are H20243899, H20243900, and H20243901.
17
06
Viwit Pharmaceuticals' Deslanoside Injection Receives Official Approval by China NMPA
May 8, 2024 – Viwit Pharmaceuticals proudly announces the receipt of the "Drug Supplementary Application Approval Notice" from the National Medical Products Administration (NMPA) for the drug product, Deslanoside Injection. The approval notice number is 2024B01980.
15
Viwit’s Levetiracetam Tablets Approved by FDA
On April 5, 2024, Viwit Pharmaceuticals' Levetiracetam Tablets received an Approval Letter (#078869) from the U.S. Food and Drug Administration (FDA), marking Viwit's first approved oral solid dosage in the United States.
04
Viwit Pharmaceuticals' Mirabegron API Receives Official Approval by China NMPA
On January 23, 2024, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by China National Medical Products Administration (NMPA) for its own proprietary active pharmaceutical ingredient (API) Mirabegron, developed independently. The issued registration number is Y20220000096, and the corresponding notice number is 2024YS00039.
26
01
Search
中文
EN
